A Single High-dose Oral Supplement of Vitamin D in Young Chinese
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200031
- Institute for Nutrition Sciences, Chinese Academy of Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, younger, Chinese Hans aged from 25-35 years, including 25 and 35 years;
- haven't taken vitamin D supplement for the past 6 months;
- with a normal BMI (18-25 kg/m2);
- with baseline serum 25(OH)D < 30 ng/ml;
- be willing to follow the instruction and complete the study.
Exclusion Criteria:
- clinically diagnosed cardiovascular disease, gastrointestinal disease, endocrine, blood, liver, lung, kidney, nerve or mental illness;
- self-reported current use of any dietary supplements containing vitamin D within the 6 months before enrollment;
- Severe anemia (hemoglobin concentration < 70 g/L);
- Serum 25(OH)D ≥ 30 ng/mL at enrollment;
- participating in other research studies within the 3 months before enrollment;
- history of drug dependence or drug abuse;
- History of heavy drinking (drinking 14 cups or more per week, equivalent to 360 mL beer or 150 mL white wine or 45 mL liquor per cup) and smokers (more than 10 cigarette per day);
- clinical abnormal of blood biochemistry, hematology or urine laboratory values;
- current pregnancy or lactation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: vitamin D3
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Effect of vitamin D3 supplementation on serum 25(OH)D changes
Time Frame: within 140 day after supplementation
|
within 140 day after supplementation
|
|
Effect of vitamin D3 supplementation on serum PTH
Time Frame: within 140 day after supplementation
|
within 140 day after supplementation
|
|
Effect of vitamin D3 supplementation on serum calcium
Time Frame: within 140 day after supplementation
|
within 140 day after supplementation
|
|
Effect of vitamin D3 supplementation on serum creatinine
Time Frame: within 140 day of supplementation
|
within 140 day of supplementation
|
|
Effect of vitamin D3 supplementation on urinary calcium / creatinine
Time Frame: within 140 day after supplementation
|
within 140 day after supplementation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Effect of vitamin D3 supplementation on fasting blood glucose
Time Frame: within 140 day after supplementation
|
within 140 day after supplementation
|
|
Effect of vitamin D3 supplementation on serum lipids
Time Frame: within 140 day after supplementation
|
within 140 day after supplementation
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRC-KY1301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.